Indian Pharma Market Hits Rs 2.24 Trillion in MAT, With 8.1% Yearly Growth

New Delhi (The Uttam Hindu): The Indian pharmaceutical market (IPM) saw a growth of 7.5% in February 2025, with several major therapies showing positive value growth, according to market research firm Pharmarack.

The cardiac, gastrointestinal, and antidiabetic therapies led the growth, with high-value increases of 9.5%, 9.6%, and 6%, respectively, contributing significantly to the overall IPM growth for the month.

Pharmarack further reported a positive 1.5% unit growth in the IPM during February 2025.

The moving annual turnover (MAT) for the IPM between March 2024 and February 2025 stood at 8.1%, resulting in a total turnover exceeding Rs 2.24 trillion. The units in the domestic market grew by 0.6%.

Leading therapy areas like cardiac, gastrointestinal, and anti-infectives, which make up around 37% of the IPM, showed strong volume growth—10.8%, 9.6%, and 5.6%, respectively.

While the top pharmaceutical players experienced modest monthly value growth in February 2025, companies such as Zydus (12.7%), Torrent Pharma (11.6%), Intas (11.4%), and Sun Pharma (10.8%) reported notable monthly value growth, with bonus units at full value among the top 20 companies in the IPM.

GSK’s antibiotic drug Augmentin and USV’s anti-diabetic drug Glycomet GP were the top-selling brands for the month, as well as in the MAT period, with sales of Rs 817 crore and Rs 800 crore, respectively, over the last year.